Melrose, MA, United States of America

Lizbeth Celeste DeSelm

USPTO Granted Patents = 13 

 

Average Co-Inventor Count = 6.1

ph-index = 4

Forward Citations = 30(Granted Patents)


Company Filing History:


Years Active: 2014-2019

Loading Chart...
Loading Chart...
13 patents (USPTO):Explore Patents

Title: Lizbeth Celeste DeSelm: Innovator in Pharmaceutical Chemistry

Introduction

Lizbeth Celeste DeSelm is a prominent inventor based in Melrose, MA (US). She has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target specific biological pathways. With a total of 13 patents to her name, her work has the potential to impact the treatment of various hyperproliferative disorders.

Latest Patents

Among her latest patents are "Substituted pyrido[3,4-d]pyrimidines and pyrido[4,3-d]pyrimidines as p70S6K inhibitors," which describes novel azaquinazoline carboxamide derivatives that can be employed for the treatment of hyperproliferative disorders. Another significant patent is "Heteroaryl compounds as IRAK inhibitors and uses thereof," which relates to compounds useful as IRAK inhibitors and their pharmaceutically acceptable compositions.

Career Highlights

Lizbeth is currently associated with Merck Patent GmbH, where she continues to innovate and develop new pharmaceutical solutions. Her work is characterized by a strong focus on creating effective inhibitors that can lead to advancements in medical treatments.

Collaborations

Throughout her career, Lizbeth has collaborated with notable colleagues, including Andreas Goutopoulos and Bayard R Huck. These partnerships have contributed to her success and the advancement of her research.

Conclusion

Lizbeth Celeste DeSelm is a trailblazer in the field of pharmaceutical chemistry, with a strong portfolio of patents that reflect her innovative spirit. Her contributions are paving the way for new treatments and therapies in the medical field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…